BR0315205A - Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo - Google Patents

Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo

Info

Publication number
BR0315205A
BR0315205A BR0315205-7A BR0315205A BR0315205A BR 0315205 A BR0315205 A BR 0315205A BR 0315205 A BR0315205 A BR 0315205A BR 0315205 A BR0315205 A BR 0315205A
Authority
BR
Brazil
Prior art keywords
protein
hybrid
preparation
nucleic acid
fusion protein
Prior art date
Application number
BR0315205-7A
Other languages
English (en)
Inventor
Michael Theisen
Soren Jepsen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of BR0315205A publication Critical patent/BR0315205A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VACINA BASEADA EM ANTìGENO CONTRA MALáRIA, PROTEìNA DE FUSãO, PROCESSO PARA A PREPARAçãO DA MESMA, áCIDO NUCLEICO, E, USO DO MESMO". Uma proteína de fusão, derivada de proteína rica em glutamato (GLURP) de P. falciparum geneticamente acoplada em proteína 3 de superfície de Merozoíto (MSP3) de P. falciparum foi produzida em Lactococcus lactis como uma proteína hibrida GLURP-MSP3 recombinante secretada e experimentos mostraram que a parte GLURP do híbrido aumentou a resposta a anticorpo total. Imunização com a proteína híbrida consistentemente gerou uma resposta de anticorpo mais forte contra os domínios de MSP3 e de GLURP individuais do que uma mistura das duas moléculas recombinantes injetadas em um sítio ou as moléculas recombinantes individuais injetadas simultaneamente em dois sítios diferentes. A diferença foi mais pronunciada para a resposta de anticorpo específico para MSP3 sugerindo que os epítopos de célula T localizados na região GLURP RO proporcionam ajuda para os epítopos de célula B na região MSP3. Ainda mais, quando os animais foram injetados com uma mistura de GLURP e MSP3, camundongos individuais tenderam a montar uma resposta de anticorpo predominante contra qualquer molécula: em alguns animais GLURP foi imunodominante enquanto que em outros animais MSP3 foi imunógena dominante. Adicionalmente, o híbrido também foi mais antigênico do que as proteínas recombinantes individuais visto que o título-ELISA de anticorpos IgG de ocorrência natural, em adultos africanos clinicamente imunes, contra a proteína híbrida foi maior do que os títulos contra as proteínas recombinantes individuais. Também foi demonstrado que a proteína híbrida é um antígeno protetor potencial porque anticorpos IgG de camundongo contra GLURP-MSP3 foram capazes de inibir o crescimento de parasita in vitro em uma maneira dependente de monócito.
BR0315205-7A 2002-11-12 2003-11-06 Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo BR0315205A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DKPA200301307 2003-09-11
PCT/DK2003/000759 WO2004043488A1 (en) 2002-11-12 2003-11-06 Malaria vaccine

Publications (1)

Publication Number Publication Date
BR0315205A true BR0315205A (pt) 2005-08-16

Family

ID=32313776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315205-7A BR0315205A (pt) 2002-11-12 2003-11-06 Vacina baseada em antìgeno contra malária, proteìna de fusão, processo para preparação da mesma, ácido nucleico, e, uso do mesmo

Country Status (14)

Country Link
US (2) US7749507B2 (pt)
EP (1) EP1567189B1 (pt)
JP (1) JP4573773B2 (pt)
CN (1) CN1741815B (pt)
AT (1) ATE432081T1 (pt)
AU (1) AU2003275949B2 (pt)
BR (1) BR0315205A (pt)
CA (1) CA2505724C (pt)
DE (1) DE60327801D1 (pt)
DK (2) DK200201741A (pt)
ES (1) ES2326415T3 (pt)
HK (1) HK1080754A1 (pt)
WO (1) WO2004043488A1 (pt)
ZA (1) ZA200504415B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) * 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
EP2818175B1 (en) * 2009-05-05 2018-11-21 Cadila Healthcare Limited Combined measles-malaria vaccine
BR112012001061B8 (pt) 2009-07-15 2021-05-25 Univ British Columbia glicosídeos 2,3-fluorados como inibidores de neuraminidase, seu método de preparação, composição farmacêutica que os compreende e embalagem comercial
EP2385107B1 (en) 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
DK2763694T3 (en) * 2011-10-04 2018-04-16 Statens Seruminstitut Preparation of a cysteine-rich protein
US20140348870A1 (en) * 2011-11-30 2014-11-27 The Regents Of The University Of California Immunogenic plasmodium falciparum antigen compositions and uses thereof
CN102533677B (zh) * 2012-01-10 2013-07-24 特菲(天津)生物医药科技有限公司 一种疟疾疫苗及其制备方法
WO2013106937A1 (en) 2012-01-19 2013-07-25 The University Of British Columbia 3' equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals
CN105652009B (zh) * 2014-11-11 2018-04-24 中国科学院苏州纳米技术与纳米仿生研究所 可用于辅助诊断疟疾的试剂盒
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
CA3031399A1 (en) * 2016-07-21 2018-01-25 Vac4All Pte. Ltd. Biofusion proteins as anti-malaria vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
AU645482B2 (en) * 1988-09-16 1994-01-20 Statens Serum Institut A malaria antigen
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
EP1390401A2 (fr) * 2001-05-16 2004-02-25 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum

Also Published As

Publication number Publication date
JP2006512926A (ja) 2006-04-20
WO2004043488A1 (en) 2004-05-27
ZA200504415B (en) 2006-03-29
AU2003275949B2 (en) 2008-06-05
AU2003275949A1 (en) 2004-06-03
CN1741815A (zh) 2006-03-01
EP1567189B1 (en) 2009-05-27
DK200201741A (da) 2003-09-16
ATE432081T1 (de) 2009-06-15
US7749507B2 (en) 2010-07-06
JP4573773B2 (ja) 2010-11-04
EP1567189A1 (en) 2005-08-31
CN1741815B (zh) 2010-05-26
DE60327801D1 (de) 2009-07-09
DK1567189T3 (da) 2009-09-14
CA2505724C (en) 2015-06-30
ES2326415T3 (es) 2009-10-09
US20110020387A1 (en) 2011-01-27
US20060024324A1 (en) 2006-02-02
CA2505724A1 (en) 2004-05-27
HK1080754A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
HK1080754A1 (en) Malaria vaccine
JP2003505431A5 (pt)
DK1682583T3 (da) Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
BR0007840A (pt) Proteìnas de fusão her-2/neu
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
ATE510912T1 (de) Zusammensetzungen und verfahren zur verbesserten expression von immunglobulinen von einem einzigen vektor unter verwendung einer peptidschnittstelle
RU2002104700A (ru) Слитые белки с Fc-фрагментом иммуноглобулина для повышения иммуногенности белковых и пептидных антигенов
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
DE602006013428D1 (de) Chimaere rekombinante antigene von toxoplasma gondii
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
JP2003530070A5 (pt)
EA200870176A1 (ru) НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
DE60038567D1 (de) Modifiziertes gp100 und dessen verwendung
ATE547529T1 (de) Materialien und verfahren im zusammenhang mit verbesserten impfstrategien
RU2009112721A (ru) Частицы с расщепленным ядром, предназначенные для презентации чужеродных молекул, прежде всего для применения в вакцинах, и способ их получения
GB0113798D0 (en) Antigens and vectors for vaccination
WO2008086386A3 (en) Adenoviral vector-based malaria vaccines
WO2003062374A3 (en) Synthetic genes for malarial proteins and methods of use
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
ATE403007T1 (de) Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen
BRPI0416736B8 (pt) construções de ácidos nucleicos, proteínas imunogênicas isoladas, cepas de leishmania geneticamente modificadas, e, processo de transfecção de um parasita de leishmania
BR0316722A (pt) Constructos genéticos e composições compreendendo rre e cte e usos destes
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.